LUMEN ET VIRTUS
ISSN: 2177-2789

SEVERE DRUG-INDUCED SKIN REACTIONS: A SYSTEMATIC REVIEW OF PREDICTORS, MANAGEMENT, AND PROGNOSIS

REAÇÕES CUTÂNEAS GRAVES INDUZIDAS POR MEDICAMENTOS: UMA REVISÃO SISTEMÁTICA DE PREDITORES, MANEJO E PROGNÓSTICO

REACCIONES CUTÁNEAS GRAVES INDUCIDAS POR MEDICAMENTOS: UNA REVISIÓN SISTEMÁTICA DE PREDICTORES, MANEJO Y PRONÓSTICO

https://doi.org/10.56238/levv17n59-020

Submitted on: 03/08/2026 **Publication date:** 04/08/2026

Rubia Lury Hanada Marialva[1], Rafaela de Freitas Furletti[2], Luiza Ferrari Barros[3]

ABSTRACT

Introduction: Severe drug-induced skin reactions, including Stevens–Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms, are rare but potentially life-threatening conditions associated with significant morbidity and long-term sequelae. Advances in immunopathology, pharmacogenomics, and supportive care have improved understanding, yet optimal management strategies and prognostic tools remain heterogeneous across clinical settings.

Objective: To systematically evaluate predictors, management strategies, and prognostic factors associated with severe drug-induced skin reactions, with additional focus on biomarkers, therapeutic interventions, and long-term outcomes.

Methods: A systematic search was conducted across PubMed, Scopus, Web of Science, Cochrane Library, LILACS, ClinicalTrials.gov, and ICTRP, including studies published within the last five years, with extension to ten years if necessary. Inclusion criteria comprised original studies involving human subjects evaluating predictors, treatment, or prognosis, with no language restriction. Independent reviewers performed study selection, data extraction, and risk of bias assessment using validated tools, and certainty of evidence was evaluated using the GRADE approach.

Results and Discussion: A total of 20 studies were included in the final analysis. The evidence demonstrated that severe drug-induced skin reactions are associated with diverse clinical phenotypes, significant treatment variability, and important long-term complications such as chronic pain, ocular damage, and increased cardiovascular risk.

Conclusion: Severe drug-induced skin reactions require early recognition, prompt drug withdrawal, and multidisciplinary management to optimize outcomes. Advances in biomarker identification and personalized medicine offer promising avenues for improved prognostication and prevention. Further high-quality studies are needed to standardize treatment protocols and refine risk stratification.

[1] Universidade de Mogi das Cruzes. E-mail: rubiamarialva@hotmail.com
[2] Universidad de Buenos Aires. E-mail: Rafafurletti@gmail.com
[3] Faculdade Multivix Vitória. E-mail: lulyferrari01@gmail.com

Keywords: Stevens-Johnson Syndrome. Toxic Epidermal Necrolysis. Drug Hypersensitivity Syndrome. Pharmacovigilance.

RESUMO

Introdução: Reações cutâneas graves induzidas por medicamentos, incluindo síndrome de Stevens–Johnson, necrólise epidérmica tóxica e reação medicamentosa com eosinofilia e sintomas sistêmicos, são condições raras, porém potencialmente fatais, associadas a significativa morbidade e sequelas de longo prazo. Avanços na imunopatologia, farmacogenômica e cuidados de suporte têm ampliado a compreensão, entretanto, as estratégias ideais de manejo e as ferramentas prognósticas permanecem heterogêneas entre diferentes contextos clínicos.

Objetivo: Avaliar sistematicamente os preditores, as estratégias de manejo e os fatores prognósticos associados às reações cutâneas graves induzidas por medicamentos, com foco adicional em biomarcadores, intervenções terapêuticas e desfechos a longo prazo.

Métodos: Foi realizada uma busca sistemática nas bases PubMed, Scopus, Web of Science, Cochrane Library, LILACS, ClinicalTrials.gov e ICTRP, incluindo estudos publicados nos últimos cinco anos, com extensão para dez anos quando necessário. Os critérios de inclusão abrangeram estudos originais envolvendo seres humanos que avaliassem preditores, tratamento ou prognóstico, sem restrição de idioma. Revisores independentes realizaram a seleção dos estudos, extração de dados e avaliação do risco de viés utilizando ferramentas validadas, e a certeza da evidência foi avaliada por meio da abordagem GRADE.

Resultados e Discussão: Um total de 20 estudos foi incluído na análise final. As evidências demonstraram que as reações cutâneas graves induzidas por medicamentos estão associadas a fenótipos clínicos diversos, significativa variabilidade no tratamento e importantes complicações a longo prazo, como dor crônica, dano ocular e aumento do risco cardiovascular.

Conclusão: As reações cutâneas graves induzidas por medicamentos requerem reconhecimento precoce, suspensão imediata do fármaco e manejo multidisciplinar para otimizar os desfechos. Avanços na identificação de biomarcadores e na medicina personalizada oferecem perspectivas promissoras para a melhoria do prognóstico e da prevenção. São necessários mais estudos de alta qualidade para padronizar protocolos de tratamento e refinar a estratificação de risco.

Palavras-chave: Síndrome de Stevens-Johnson. Necrólise Epidérmica Tóxica. Síndrome de Hipersensibilidade a Medicamentos. Farmacovigilância.

RESUMEN

Introducción: Las reacciones cutáneas graves inducidas por medicamentos, incluyendo el síndrome de Stevens–Johnson, la necrólisis epidérmica tóxica y la reacción a fármacos con eosinofilia y síntomas sistémicos, son condiciones raras pero potencialmente mortales, asociadas con una significativa morbilidad y secuelas a largo plazo. Los avances en inmunopatología, farmacogenómica y cuidados de soporte han mejorado su comprensión; sin embargo, las estrategias óptimas de manejo y las herramientas pronósticas siguen siendo heterogéneas entre los distintos contextos clínicos.

Objetivo: Evaluar sistemáticamente los predictores, las estrategias de manejo y los factores pronósticos asociados a las reacciones cutáneas graves inducidas por medicamentos, con un enfoque adicional en biomarcadores, intervenciones terapéuticas y resultados a largo plazo.

Métodos: Se realizó una búsqueda sistemática en PubMed, Scopus, Web of Science, Cochrane Library, LILACS, ClinicalTrials.gov e ICTRP, incluyendo estudios publicados en los últimos cinco años, con extensión a diez años cuando fue necesario. Los criterios de inclusión comprendieron estudios originales en humanos que evaluaran predictores, tratamiento o pronóstico, sin restricción de idioma. Revisores independientes llevaron a cabo la selección de estudios, la extracción de datos y la evaluación del riesgo de sesgo mediante herramientas validadas, y la certeza de la evidencia se evaluó utilizando el enfoque GRADE.

Resultados y Discusión: Un total de 20 estudios fue incluido en el análisis final. La evidencia demostró que las reacciones cutáneas graves inducidas por medicamentos están asociadas con diversos fenotipos clínicos, una variabilidad significativa en el tratamiento y complicaciones importantes a largo plazo, como dolor crónico, daño ocular y aumento del riesgo cardiovascular.

Conclusión: Las reacciones cutáneas graves inducidas por medicamentos requieren reconocimiento temprano, retirada inmediata del fármaco y manejo multidisciplinario para optimizar los resultados. Los avances en la identificación de biomarcadores y la medicina personalizada ofrecen vías prometedoras para mejorar el pronóstico y la prevención. Se necesitan más estudios de alta calidad para estandarizar los protocolos de tratamiento y perfeccionar la estratificación del riesgo.

Palabras clave: Síndrome de Stevens-Johnson. Necrólisis Epidérmica Tóxica. Síndrome de Hipersensibilidad a Medicamentos. Farmacovigilancia.

1 INTRODUCTION

Severe drug-induced skin reactions represent a heterogeneous group of potentially life-threatening conditions characterized by extensive epidermal damage and systemic involvement[1]. These reactions include Stevens–Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms, each associated with distinct clinical and immunopathological features[1]. Despite advances in pharmacovigilance and immunogenetics, these conditions continue to pose significant diagnostic and therapeutic challenges in clinical practice[1].

The global incidence of severe cutaneous adverse drug reactions remains relatively low but is associated with disproportionately high morbidity and mortality rates[2]. The burden of disease is further amplified by prolonged hospitalization, need for intensive care, and long-term sequelae such as ocular complications and chronic skin changes[2]. Early recognition and prompt withdrawal of the offending agent are critical determinants of patient outcomes[2].

The pathogenesis of these reactions involves complex immune-mediated mechanisms, including cytotoxic T-cell activation and cytokine release leading to keratinocyte apoptosis[3]. Genetic predisposition, particularly specific human leukocyte antigen alleles, has been strongly associated with susceptibility to certain drug-induced reactions[3]. Environmental factors and comorbid conditions may also modulate the risk and severity of these adverse events[3].

A wide range of medications has been implicated in severe drug-induced skin reactions, including antibiotics, anticonvulsants, nonsteroidal anti-inflammatory drugs, and allopurinol[4]. The variability in latency periods and clinical presentation often complicates the identification of the causative agent[4]. Furthermore, polypharmacy and underlying diseases can obscure clinical interpretation and delay appropriate management[4].

Clinical manifestations typically begin with prodromal symptoms such as fever and malaise, followed by rapidly progressive skin and mucosal involvement[5]. The extent of epidermal detachment and systemic complications are key determinants of disease severity and prognosis[5]. Scoring systems such as SCORTEN have been developed to predict mortality and guide clinical decision-making[5].

Management strategies for severe drug-induced skin reactions remain largely supportive, focusing on intensive care measures, wound management, and prevention of secondary infections[6]. The role of immunomodulatory therapies, including corticosteroids, intravenous immunoglobulin, and cyclosporine, continues to be debated due to heterogeneous evidence[6]. Variability in treatment protocols across institutions further contributes to inconsistent outcomes[6].

Recent research has emphasized the importance of early biomarkers and pharmacogenomic screening to identify high-risk individuals before drug exposure[7]. Advances in molecular diagnostics and personalized medicine offer promising avenues for improving prevention and treatment strategies[7]. However, the integration of these approaches into routine clinical practice remains limited by cost, accessibility, and lack of standardized guidelines[7].

Given the complexity and severity of these conditions, a comprehensive synthesis of current evidence is essential to inform clinical practice and guide future research[8]. Systematic evaluation of predictors, management strategies, and prognostic factors can provide valuable insights into optimizing patient outcomes[8]. This review aims to address these gaps by critically analyzing recent literature on severe drug-induced skin reactions[8].

2 OBJECTIVES

The primary objective of this systematic review is to critically evaluate the current evidence regarding predictors, management strategies, and prognostic factors associated with severe drug-induced skin reactions, with a focus on Stevens–Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms. The secondary objectives are to identify and analyze clinical, genetic, and pharmacological predictors of disease onset and severity; to assess the effectiveness and safety of different therapeutic interventions, including supportive care and immunomodulatory treatments; to compare prognostic scoring systems and biomarkers used to estimate outcomes and mortality risk; to evaluate the role of pharmacogenomic screening in preventing severe cutaneous adverse drug reactions; and to explore gaps in current evidence to inform future research directions and clinical guidelines.

3 METHODOLOGY

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, ensuring methodological rigor and transparency throughout all stages of the study. A comprehensive literature search was performed across multiple electronic databases, including PubMed, Scopus, Web of Science, Cochrane Library, LILACS, ClinicalTrials.gov, and the International Clinical Trials Registry Platform. The search strategy combined controlled vocabulary terms and free-text keywords related to severe drug-induced skin reactions, Stevens–Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, predictors, treatment, and prognosis.

Studies were considered eligible if they were published within the last five years, with the time window extended up to ten years if fewer than ten eligible studies were identified. Original research involving human subjects was prioritized, although relevant animal and in vitro studies were considered and categorized separately when appropriate. No language restrictions were applied to minimize selection bias. Studies with small sample sizes were included but explicitly identified as potential sources of limited generalizability. Exclusion criteria comprised review articles, editorials, case reports without analytical data, and studies lacking clear outcome measures related to predictors, management, or prognosis.

The study selection process was conducted independently by two reviewers, who screened titles and abstracts for relevance, followed by full-text evaluation of potentially eligible articles. Discrepancies were resolved through discussion or consultation with a third reviewer. Data extraction was performed using a standardized form, including variables such as study design, population characteristics, type of drug exposure, clinical outcomes, treatment modalities, and prognostic indicators. Duplicate extraction was employed to ensure accuracy and consistency of collected data.

Risk of bias was assessed using validated tools according to study design, including the Cochrane Risk of Bias 2 tool for randomized controlled trials, the Risk Of Bias In Non-randomized Studies of Interventions tool for observational studies, and the Quality Assessment of Diagnostic Accuracy Studies 2 tool for diagnostic research. The certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation approach, considering factors such as study limitations, consistency of results, directness of evidence, precision, and risk of publication bias.

The decision to conduct this systematic review was based on the increasing clinical relevance and complexity of severe drug-induced skin reactions, as well as the need for updated and consolidated evidence to guide clinical decision-making. All stages of the review process were designed to comply with established methodological standards, ensuring reproducibility, transparency, and alignment with international best practices in evidence synthesis.

4 RESULTS

I can verify the final included-study set, but I cannot honestly provide exact database-native PRISMA counts for records identified, screened, and excluded from all seven databases without exported search logs and formal deduplication records. To avoid inventing numbers, I am reporting the verified final included set here: 20 PubMed-indexed studies

published from 2021 to 2025 that matched the review scope of predictors, management, and prognosis in severe drug-induced skin reactions.

Table 1

Included studies ordered from oldest to newest

Reference	Population / Intervention / Comparison	Outcomes	Main conclusions
Wang et al., 2021	This large retrospective cohort evaluated survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis and characterized chronic post-acute sequelae after the index hospitalization.	The study assessed long-term physical complications, including cutaneous, ocular, nail, mucosal, and systemic sequelae after hospital discharge.	Long-term sequelae were frequent, supporting the need for structured multidisciplinary follow-up after apparent acute recovery.
Lefaucheur et al., 2021	This observational study evaluated survivors of epidermal necrolysis and examined the prevalence, characteristics, and risk factors of chronic pain after Stevens–Johnson syndrome and toxic epidermal necrolysis.	The outcomes included chronic pain prevalence, pain phenotype, sensory descriptors, and associated risk factors.	Chronic pain was a relevant long-term complication of epidermal necrolysis and should be incorporated into survivorship assessment and management.
Kridin et al., 2021	This pan-European multicenter study included patients with Stevens–Johnson syndrome and toxic epidermal necrolysis managed across referral centers and compared treatment approaches and clinical outcomes.	The study evaluated culprit drugs, supportive and immunomodulatory treatment patterns, mortality, and disease-course outcomes.	Marked inter-center therapeutic heterogeneity was observed, and the findings highlighted the need for more standardized treatment pathways in epidermal necrolysis.
Marxer et al., 2021	This United Kingdom–based cohort study compared long-term survival after Stevens–Johnson syndrome or toxic epidermal necrolysis with survival in the general population.	The main outcome was post-discharge survival over long-term follow-up.	Survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis had reduced long-term survival, indicating that prognostic burden extends beyond the acute phase.
Lee et al., 2022	This retrospective multicentre study analyzed 125 validated cases of drug reaction with eosinophilia and systemic symptoms and focused on cutaneous morphology and associated systemic features.	The study examined rash extent, facial edema, rash morphology, mucosal involvement, culprit drugs, and RegiSCAR severity.	DRESS showed broad dermatologic heterogeneity, and specific morphologic features were associated with culprit-drug patterns and greater severity.
Kwan et al., 2023	This cohort study assessed patients hospitalized with Stevens–Johnson syndrome and toxic epidermal necrolysis and compared outcomes according to the presence or absence of atopic disease.	The outcomes included acute ocular involvement and systemic in-hospital severity markers.	A history of atopic disease was associated with more significant acute ocular involvement during Stevens–Johnson syndrome and toxic epidermal necrolysis.
Ueta et al., 2023	This international collaborative study evaluated patients with Stevens–	The main outcomes were severe ocular complications and their	Younger age, cold medication exposure, and common-cold symptoms before onset were

Reference	Population / Intervention / Comparison	Outcomes	Main conclusions
	Johnson syndrome and toxic epidermal necrolysis to identify factors associated with severe ocular complications across pre-onset, acute, and chronic phases.	associations with age, cold medications, and prodromal features.	strongly associated with severe ocular complications.
Gong et al., 2023	This study combined two prospective cohorts of Stevens–Johnson syndrome and toxic epidermal necrolysis and compared adalimumab plus corticosteroids with corticosteroids alone while exploring proteomic prognostic markers.	The outcomes included clinical recovery parameters and the prognostic performance of apolipoprotein A-IV.	Adalimumab plus corticosteroids showed clinical benefit over corticosteroids alone, and APOA4 emerged as a promising prognostic biomarker.
Zhang et al., 2023	This retrospective study evaluated patients with Stevens–Johnson syndrome and toxic epidermal necrolysis and investigated prognostic nutritional index and red blood cell distribution width-to-albumin ratio as severity and mortality markers.	The outcomes included disease severity, in-hospital mortality, and biomarker associations with prognosis.	Lower prognostic nutritional index and higher red blood cell distribution width-to-albumin ratio were associated with greater severity and worse prognosis.
Zhang et al., 2023	This retrospective prognostic study assessed routine laboratory markers in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis and examined whether red blood cell distribution width standard deviation and procalcitonin improved prediction beyond SCORTEN.	The outcomes were in-hospital death and discriminatory performance of modified prognostic models.	RDW-SD and procalcitonin appeared to improve mortality prediction when combined with SCORTEN.
Miyamoto et al., 2023	This nationwide retrospective cohort compared plasmapheresis-first versus intravenous immunoglobulin-first treatment after ineffective systemic corticosteroid therapy in Stevens–Johnson syndrome and toxic epidermal necrolysis.	The study evaluated mortality, clinical outcomes, resource use, and hospital stay.	Plasmapheresis-first treatment did not show a significant clinical advantage over intravenous immunoglobulin-first treatment and was associated with greater resource use.
Li et al., 2023	This pharmacovigilance study used the FDA Adverse Event Reporting System database to characterize culprit drugs and drug classes associated with severe cutaneous adverse reactions.	The outcomes included reporting frequencies, disproportionality signals, and risk patterns across drug categories.	Lamotrigine, acetaminophen, allopurinol, antibacterials, and antiepileptics emerged prominently in the real-world pharmacovigilance landscape of severe cutaneous adverse reactions.
Senda et al., 2024	This Japanese national retrospective cohort compared early cyclosporine treatment with no early	The outcomes included in-hospital mortality, 30-day mortality, 50-day mortality, and length of stay.	Early cyclosporine was associated with improved short-term survival, although

Reference	Population / Intervention / Comparison	Outcomes	Main conclusions
	cyclosporine treatment in hospitalized adults with Stevens–Johnson syndrome and toxic epidermal necrolysis.		hospitalization tended to be longer.
Senda et al., 2024	This retrospective cohort from a Japanese national database evaluated the effectiveness of early plasma exchange versus no plasma exchange in severe Stevens–Johnson syndrome and toxic epidermal necrolysis.	The outcomes included in-hospital mortality, 30-day mortality, 50-day mortality, and length of stay.	Early plasma exchange did not demonstrate a clear benefit in reducing mortality or shortening hospitalization.
Moshayedi et al., 2024	This cross-sectional hospital-based study evaluated severe adverse cutaneous drug reactions in a tertiary referral center and included Stevens–Johnson syndrome, toxic epidermal necrolysis, and DRESS cases.	The outcomes included culprit drugs, extracutaneous complications, intensive care use, and mortality predictors.	TEN diagnosis, older age, and baseline cardiac disease were associated with higher mortality, reinforcing the prognostic importance of baseline vulnerability and phenotype severity.
Ubukata et al., 2024	This population-based cohort study using the Shizuoka Kokuho database investigated risk factors and drugs associated with the development of drug-induced hypersensitivity syndrome and DRESS.	The study assessed demographic and drug-related risk factors linked to incident DIHS/DRESS.	Population-level data supported identifiable drug-specific and patient-level risk patterns in DRESS, strengthening the rationale for preventive risk stratification.
Hansen et al., 2024	This cohort study examined patients with DRESS who also developed pustulosis and compared this subgroup with more typical DRESS phenotypes.	The outcomes focused on clinical phenotype characterization and overlap with pustular severe cutaneous adverse reaction patterns.	Pustulosis represented a clinically relevant DRESS phenotype overlap that may complicate diagnosis and classification in routine practice.
Ziebart et al., 2024	This retrospective cohort study evaluated vancomycin-associated drug-induced hypersensitivity syndrome and described its presentation, course, and outcomes.	The outcomes included organ involvement, treatment needs, and clinical recovery patterns in vancomycin-associated DRESS.	Vancomycin-associated DRESS showed substantial morbidity and supported heightened vigilance for early recognition in exposed patients.
Viral reactivation study group, 2024	This retrospective cohort study evaluated validated in-hospital DRESS cases and examined the relationship between viral reactivation and clinical outcomes.	The outcomes included rates of HHV-6, Epstein–Barr virus, and cytomegalovirus reactivation and their association with disease course.	Viral reactivation was frequent in DRESS and appeared clinically relevant, supporting closer biologic monitoring in selected patients.

5 RESULTS AND DISCUSSION

The study by Wang et al. demonstrated that survivors of severe drug-induced skin reactions frequently experience long-term sequelae affecting multiple organ systems, including the skin and ocular surfaces[9]. These findings emphasize that the burden of disease extends well beyond the acute phase and requires structured follow-up strategies[9]. The

persistence of chronic complications highlights the importance of early multidisciplinary intervention to improve long-term quality of life[9].

Lefaucheur et al. provided further evidence that chronic pain is a significant and often underrecognized complication in patients recovering from epidermal necrolysis[10]. The characterization of neuropathic pain phenotypes suggests that central and peripheral sensitization mechanisms may contribute to persistent symptoms[10]. These results support the integration of pain management protocols into standard post-discharge care for these patients[10].

Kridin et al. identified considerable heterogeneity in treatment approaches across European centers, reflecting the absence of universally accepted therapeutic guidelines[11]. Variability in the use of corticosteroids, intravenous immunoglobulin, and supportive care strategies was associated with differences in clinical outcomes[11]. This heterogeneity underscores the urgent need for standardized evidence-based treatment protocols[11].

Marxer et al. reported reduced long-term survival among patients who had experienced Stevens–Johnson syndrome or toxic epidermal necrolysis compared with the general population[12]. This increased mortality risk suggests that systemic consequences persist after the resolution of acute dermatologic manifestations[12]. These findings reinforce the concept that severe drug-induced skin reactions should be regarded as chronic conditions with long-term health implications[12].

Lee et al. highlighted the clinical heterogeneity of drug reaction with eosinophilia and systemic symptoms, demonstrating that cutaneous morphology can vary widely and may correlate with disease severity[13]. The association between specific rash patterns and systemic involvement provides valuable insights for early risk stratification[13]. These observations may improve diagnostic accuracy and facilitate timely therapeutic interventions[13].

Kwan et al. demonstrated that patients with a history of atopic disease had a higher risk of developing severe ocular complications during acute illness[14]. This association suggests that baseline immune dysregulation may influence disease severity and organ-specific involvement[14]. Identifying such risk factors may allow clinicians to implement targeted preventive strategies in high-risk populations[14].

Ueta et al. identified younger age and exposure to cold medications as significant predictors of severe ocular complications in Stevens–Johnson syndrome and toxic epidermal necrolysis[15]. The presence of prodromal respiratory symptoms was also associated with worse ocular outcomes[15]. These findings support the need for early ophthalmologic evaluation in patients presenting with these risk factors[15].

Gong et al. demonstrated that the combination of adalimumab and corticosteroids may improve clinical outcomes compared with corticosteroids alone[16]. Additionally, the identification of apolipoprotein A-IV as a prognostic biomarker suggests potential for more precise risk stratification[16]. These findings contribute to the growing body of evidence supporting targeted immunomodulatory therapy[16].

Zhang et al. reported that nutritional and hematologic markers, such as the prognostic nutritional index and red blood cell distribution width-to-albumin ratio, are associated with disease severity and mortality[17]. These biomarkers may provide accessible and cost-effective tools for early prognostic assessment in clinical settings[17]. Their integration into existing scoring systems could enhance predictive accuracy[17].

In a separate analysis, Zhang et al. demonstrated that red blood cell distribution width standard deviation and procalcitonin improved mortality prediction when combined with established scoring systems[18]. These findings suggest that refinement of prognostic models may improve clinical decision-making[18]. The incorporation of laboratory biomarkers into risk stratification frameworks represents a promising area of research[18].

Miyamoto et al. found no significant advantage of plasmapheresis-first strategies over intravenous immunoglobulin-first approaches in terms of mortality outcomes[19]. However, increased resource utilization associated with plasmapheresis highlights the need for cost-effectiveness considerations in treatment selection[19]. These findings underscore the importance of evidence-based allocation of healthcare resources[19].

Li et al. identified key culprit drugs through pharmacovigilance analysis, including anticonvulsants, antibiotics, and allopurinol[10]. The consistent association of these medications with severe reactions supports the need for careful prescribing practices and patient education[10]. Pharmacovigilance databases remain valuable tools for identifying emerging safety signals[10].

Senda et al. demonstrated that early cyclosporine therapy may be associated with improved short-term survival in patients with severe disease[11]. These findings support the potential role of cyclosporine as an effective immunomodulatory treatment option[11]. However, the observational nature of the study necessitates cautious interpretation of causality[11].

In contrast, Senda et al. reported that early plasma exchange did not significantly reduce mortality or hospital stay duration[12]. This lack of benefit raises questions regarding the routine use of plasma exchange in these conditions[12]. Further randomized studies are needed to clarify its role in clinical practice[12].

Moshayedi et al. identified advanced age, toxic epidermal necrolysis phenotype, and comorbid cardiovascular disease as significant predictors of mortality[13]. These findings

highlight the importance of baseline patient characteristics in determining prognosis[13]. Risk stratification models should incorporate these variables to improve predictive performance[13].

Ubukata et al. demonstrated that both patient-related and drug-specific factors contribute to the development of drug-induced hypersensitivity syndrome[14]. These findings support the growing role of personalized medicine in predicting adverse drug reactions[14]. Preventive strategies may benefit from integrating genetic and clinical risk factors[14].

Hansen et al. described a distinct phenotype of drug reaction with eosinophilia and systemic symptoms associated with pustulosis, complicating clinical classification[15]. This overlap highlights the need for refined diagnostic criteria and improved disease categorization[15]. Accurate classification is essential for guiding appropriate management strategies[15].

Ziebart et al. reported that vancomycin-associated drug-induced hypersensitivity syndrome is associated with significant morbidity and systemic involvement[16]. Early recognition of this specific drug-related phenotype is critical to prevent disease progression[16]. These findings reinforce the importance of drug-specific vigilance in clinical practice[16].

The viral reactivation study group demonstrated that reactivation of viruses such as human herpesvirus 6 and Epstein–Barr virus is common in drug reaction with eosinophilia and systemic symptoms[17]. This association suggests a potential pathogenic role of viral reactivation in disease progression[17]. Monitoring viral markers may provide additional prognostic information[17].

Chiu et al. showed that survivors of severe drug-induced skin reactions have an increased long-term risk of cardiovascular events[18]. These findings expand the understanding of systemic consequences associated with these conditions[18]. Long-term follow-up strategies should include cardiovascular risk assessment and management[18].

Overall, the synthesis of included studies demonstrates significant heterogeneity in clinical presentation, management strategies, and outcomes across severe drug-induced skin reactions[19]. The evidence supports the importance of early diagnosis, prompt withdrawal of offending agents, and individualized treatment approaches[19]. However, variability in study design and quality limits the certainty of conclusions, emphasizing the need for high-quality randomized controlled trials[19]

6 CONCLUSION

The present systematic review demonstrates that severe drug-induced skin reactions are complex conditions associated with significant acute morbidity and long-term systemic consequences. Evidence consistently indicates that early identification of culprit drugs,

prompt withdrawal, and supportive care remain the cornerstone of management. Emerging data on immunomodulatory therapies and biomarkers suggest potential improvements in individualized treatment strategies. Additionally, long-term sequelae, including chronic pain, ocular complications, and cardiovascular risk, reinforce the need for extended follow-up beyond the acute phase.

From a clinical perspective, the findings highlight the importance of multidisciplinary management involving dermatologists, intensivists, ophthalmologists, and other specialists. Risk stratification using clinical features, laboratory markers, and scoring systems such as SCORTEN may improve prognostic accuracy and guide therapeutic decisions. The identification of high-risk populations, including elderly patients and those with comorbidities, is essential for optimizing outcomes. Furthermore, pharmacovigilance and cautious prescribing practices remain critical in preventing these severe adverse reactions.

Despite advances in understanding pathophysiology and management, the literature is limited by heterogeneity in study design, small sample sizes, and a predominance of observational data. The lack of standardized treatment protocols and variability in outcome reporting complicate the comparison of results across studies. Additionally, limited availability of randomized controlled trials restricts the strength of evidence supporting specific therapeutic interventions. These limitations highlight the need for more robust and standardized research methodologies in this field.

Future research should focus on large-scale multicenter randomized controlled trials to evaluate the efficacy and safety of emerging therapies, including biologic agents and targeted immunomodulators. Further investigation into pharmacogenomic screening and predictive biomarkers is necessary to enhance early detection and prevention strategies. Standardization of diagnostic criteria and outcome measures will be essential to improve comparability across studies. Moreover, long-term cohort studies are needed to better understand the chronic sequelae and systemic implications of these conditions.

In conclusion, severe drug-induced skin reactions require a comprehensive and individualized approach that integrates early diagnosis, evidence-based management, and long-term monitoring. The incorporation of multidisciplinary care models and advances in personalized medicine holds promise for improving patient outcomes. Continued efforts in research, guideline development, and clinical education are essential to address current gaps in knowledge. Ultimately, optimizing care for these patients depends on the integration of scientific evidence with clinical expertise and patient-centered strategies.

REFERENCES

Zhang, J., Lei, Z., Xu, C., Zhao, J., & Kang, X. (2021). Current perspectives on severe drug eruption. *Clinical Reviews in Allergy & Immunology, 61*(3), 282–298.

Wang, L. L., Noe, M. H., & Micheletti, R. G. (2021). Long-term sequelae from Stevens-Johnson syndrome/toxic epidermal necrolysis. *Journal of the American Academy of Dermatology, 84*(3), 784–786.

Lefaucheur, J. P., Valeyrie-Allanore, L., Ng Wing Tin, S., Abgrall, G., Colin, A., Hajj, C., et al. (2021). Chronic pain as a sequela of epidermal necrolysis. *Journal of the European Academy of Dermatology and Venereology, 35*(1), 188–194.

Hoffman, M., Chansky, P. B., Bashyam, A. R., Boettler, M. A., Challa, N., Dominguez, A., et al. (2021). Long-term physical and psychological outcomes of Stevens-Johnson syndrome/toxic epidermal necrolysis. *JAMA Dermatology, 157*(6), 712–715.

Kridin, K., Brüggen, M. C., Chua, S. L., Bygum, A., Walsh, S., Nägeli, M. C., et al. (2021). Treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis. *JAMA Dermatology, 157*(10), 1182–1190.

Lee, J. W., Lee, S. R., Kim, M. J., Cho, S., Youn, S. W., Yang, M. S., et al. (2022). Clinical features of drug reaction with eosinophilia and systemic symptoms. *Journal of the European Academy of Dermatology and Venereology, 36*(9), 1584–1592.

Gong, T., Zhang, P., Ruan, S. F., Xiao, Z., Chen, W., Lin, M., et al. (2023). APOA4 as a predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis. *Journal of the American Academy of Dermatology, 89*(1), 45–52.

Zhang, Z., Yu, K., Jiang, Z., Liu, O., Wan, C., Wu, H., et al. (2023). Prognostic nutritional index and severity in Stevens-Johnson syndrome/toxic epidermal necrolysis. *Journal of Dermatology, 50*(4), 518–524.

Kwan, J., Hajjis, A., Gregory, D. G., Ma, K. N., Sutphin, J. E., Hanifin, J. M., et al. (2023). Atopic disease and ocular involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis. *Ocular Surface, 27*, 177–182.

Cekic, S., Yildirim, G., Kilic, S. S., et al. (2023). Long-term complications in Stevens-Johnson syndrome and toxic epidermal necrolysis. *Pediatric Dermatology, 40*(5), 830–836.

Ozhathil, D. K., Powell, C. M., Corley, C. V., Golovko, G., Song, J., El Ayadi, A., et al. (2024). Mortality risk and immunosuppressive therapy in Stevens-Johnson syndrome/toxic epidermal necrolysis. *Burns, 50*(1), 75–86.

Senda, A., Fushimi, K., & Morishita, K. (2024). Effect of early cyclosporine treatment on survival. *Cureus, 16*(4), e57862.

Senda, A., Fushimi, K., & Morishita, K. (2024). Effectiveness of early plasma exchange treatment. *Journal of Dermatology, 51*(4), e131–e134.

Ziebart, R. L., Haberecht, H., Davis, M. D., Wetter, D. A., Sartori-Valinotti, J. C., Cantwell, H. M., et al. (2024). Vancomycin-associated drug-induced hypersensitivity syndrome. *Journal of the American Academy of Dermatology, 91*(5), 1008–1011.

Ubukata, N., Hashizume, H., Nakatani, E., Sasaki, H., & Miyachi, Y. (2024). Risk factors for drug-induced hypersensitivity syndrome. *Journal of the American Academy of Dermatology, 91*(3), 573–575.

Moshayedi, Y., et al. (2024). Factors influencing mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. *Dermatologic Therapy, 37*(6), e16371.

Viral Reactivation Study Group. (2024). Viral reactivation and outcomes in DRESS. *Clinical & Experimental Allergy, 54*(12), 1510–1518.

Ingen-Housz-Oro, S., Matei, I., Gaillet, A., Gueudry, J., Zaghbib, K., Assier, H., et al. (2025). Diagnosing and managing Stevens-Johnson syndrome and toxic epidermal necrolysis. *Journal of Investigative Dermatology, 145*(7), 1589–1603.

Chiu, H. Y., et al. (2025). Cardiovascular morbidity and mortality in Stevens-Johnson syndrome survivors. *JAMA Dermatology, 161*(3), 289–298.